I/ONX Shatters the Host Tax: New Symphony SixtyFour Architecture Delivers 50% TCO Savings Across AI Inference and Fine-Tuning Lifecycle
22.4.2026 16:00:00 EEST | Business Wire | Press release
I/ONX High Performance Compute (HPC), a leading provider of heterogeneous AI systems, today announced the global launch of the Symphony SixtyFour, a high-density platform designed to collapse the physical and economic footprint of AI inference and fine-tuning infrastructure. By supporting up to 64 accelerators on a single node, I/ONX eliminates the redundant Host Tax—the massive overhead in power, hardware, and licensing that negatively impacts ROI in enterprise AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422485327/en/
I/ONX Introduces Symphony SixtyFour: The Host Tax is Over. Save 30-50% on your AI Infrastructure Costs.
While inference now accounts for 90% of enterprise AI workloads, enterprises are entirely limited to deploying inference on training hardware platforms. Symphony SixtyFour provides significant advantages for reduced CapEx and OpEx for inference and fine-tuning workloads. In training comparisons, the I/ONX system recovers the 30kW Host Tax typically wasted on redundant CPUs, memory, and support hardware in multi-node clusters and simplifies ongoing support tasks. For production-scale inference on alternative accelerators, the platform is even more transformative, drawing one-fourth the power of a traditional 64-device cluster—completely eliminating liquid cooling needs for inference only.
“Enterprise AI infrastructure is entering a new phase of maturity,” said I/ONX CEO Justyn Hornor. “The training-centric designs of the past served us well during the experimental phase, but they weren't optimized for the power-constrained, production-heavy world we live in today. With Symphony SixtyFour, we’ve reimagined the stack to be more fluid and fit for purpose, allowing organizations to master massive-scale inference while finally eliminating the unnecessary infrastructure waste that has hindered ROI.”
The Symphony SixtyFour Advantage: Fit for purpose Silicon. The platform is engineered to maximize every watt and dollar for Enterprise AI.
- Eliminating the Training Host Tax: For large-scale inference and fine-tuning, Symphony SixtyFour collapses the infrastructure stack from eight nodes into one. This consolidation removes up to 30kW of wasted support power, allowing for higher compute density within existing power envelopes.
- Zero-Hop, near-Deterministic Performance: By housing 64 accelerators within a single OS instance, Symphony SixtyFour eliminates the East-West network latency.
- Heterogeneous Flexibility: Symphony SixtyFour is fully vendor-neutral and built for mixed-mode operations. Enterprises can seamlessly pair high-end GPUs (including AMD/NVIDIA) with more purpose built, low power co-processors and layer in specialized inference silicon (Axelera/FuriosaAI/Tenstorrent) future-proofing infrastructure against shifting market dynamics.
- Collapsing OpEx by simplifying the Host Tax: Beyond hardware and power, Symphony SixtyFour provides massive operational relief. By presenting a 64-device fleet through a single management environment, I/ONX collapses the Software Tax, saving enterprises up to $500,000 annually in Enterprise Operating Systems and orchestration licensing per cluster.
I/ONX accelerates the enterprise shift toward systems designed specifically for inference and fine-tuning at scale. Symphony SixtyFour is available now, enabling organizations to reclaim critical power capacity and reduce costs. I/ONX is committed to delivering high-density infrastructure required to unlock the maximum economic and operational potential of production AI.
About I/ONX
I/ONX High Performance Compute (HPC) is the pioneer of heterogeneous AI infrastructure, and is redefining the AI lifecycle by eliminating the Host Tax of legacy architectures. The I/ONX flagship Symphony SixtyFour consolidates up to 64 accelerators into a single node, reducing rack-scale TCO by 50% or more. By dramatically lowering power consumption and maximizing hardware utilization, I/ONX enables enterprises to achieve production-scale AI with unprecedented efficiency and faster ROI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422485327/en/
Contacts
I/ONX High Performance Compute
media@i-onx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom